Caris Life Sciences Inc (CAI)
Caris Life Sciences Inc is a healthcare company focused on biotechnology and precision oncology. Based in Irving, Texas, the company develops and commercializes molecular profiling solutions that use molecular information together with artificial intelligence and machine learning to support healthcare decision-making. Its product portfolio includes tissue-based, blood-based, and whole-genome sequencing platforms, as well as offerings for multi-cancer early detection, minimal residual disease, and therapy selection in hematological cancers. Caris also provides pharmaceutical research and development services, including laboratory delivery, strategic data, and research support, to biopharmaceutical customers. The company serves hospitals, institutions, patients, and pharma clients in the United States and internationally.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CAI
|
$17.73
|
12.7% Upside
|
Fair
|
$27
|
71.5% Upside
|
Bargain
|
Great
|
—
|
—
|
—
|
0.0%
|
August 5, 2026
|
-10.8x
|
7.5x
|
4.9x
|
4.399 B
|
4.057 B
|
8.9%
|
36.5%
|
3.5
|
—
|
-30.0%
|
